Oruka Therapeutics (ORKA) Net Income (2010 - 2024)
Oruka Therapeutics (ORKA) posted quarterly Net Income of -$18.1 million for Q2 2024, down 1085.44% year-over-year from $1.8 million in Q3 2023, and down 157.93% quarter-over-quarter from -$7.0 million in Q1 2024.
Oruka Therapeutics (ORKA) Net Income (2010 - 2024) Analysis & Trends
Oruka Therapeutics' Net Income history runs 15 years deep, the most recent figure standing at -$18.1 million for Q2 2024.
- In Q2 2024, Net Income fell 1085.44% year-over-year to -$18.1 million; the TTM figure through Mar 2025 stood at -$18.1 million (down 58.4% YoY), while the FY2023 annual figure was -$60.9 million, up 5.32% from the prior year.
- Net Income for Q2 2024 stood at -$18.1 million, down from -$7.0 million in the prior quarter.
- The five-year high for Net Income was -$1.1 million in Q4 2023, with the low at -$18.1 million in Q2 2024.
- The 5-year median for Net Income is -$2.8 million (2022), against an average of -$3.9 million.
- The sharpest annual moves came in 2022 and 2024: Net Income soared 79.32% in 2022, then tumbled 1085.44% in 2024.
- Oruka Therapeutics' Net Income stood at -$5.2 million in 2020, then retreated by 8.24% to -$5.7 million in 2021, then jumped by 79.32% to -$1.2 million in 2022, then increased by 5.03% to -$1.1 million in 2023, then slumped by 1521.35% to -$18.1 million in 2024.
- Business Quant data shows ORKA's Net Income at -$18.1 million in Q2 2024, -$7.0 million in Q1 2024, and -$1.1 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -18.08 Mn |
| Mar 31, 2024 | -7.01 Mn |
| Dec 31, 2023 | -1.12 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | -1.53 Mn |
| Mar 31, 2023 | -1.38 Mn |
| Dec 31, 2022 | -1.17 Mn |
| Sep 30, 2022 | -2.40 Mn |
| Jun 30, 2022 | -3.65 Mn |
| Mar 31, 2022 | -3.30 Mn |
| Dec 31, 2021 | -5.68 Mn |
| Sep 30, 2021 | -4.71 Mn |
| Jun 30, 2021 | -4.83 Mn |
| Mar 31, 2021 | -4.11 Mn |
| Dec 31, 2020 | -5.24 Mn |
| Sep 30, 2020 | -1.99 Mn |
| Jun 30, 2020 | -1.30 Mn |
| Mar 31, 2020 | -1.32 Mn |
| Dec 31, 2019 | -1.23 Mn |
| Sep 30, 2019 | -1.16 Mn |